{"id":"W2623329013","doi":"10.1002/hon.2438_50","title":"PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE <scp>B</scp>‐CELL LYMPHOMA (<scp>RRPMBCL</scp>): UPDATED RESULTS FROM THE <scp>KEYNOTE</scp>‐013 TRIAL","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Neutropenia; Internal medicine; Pembrolizumab; Regimen; Adverse effect; Population; Cohort; Refractory (planetary science); Surgery; Oncology; Gastroenterology; Toxicity; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001588819,0.0007862838,0.00237493,0.0002516729,0.0005317579,0.00007771721,0.001223153,0.001089246,0.00005738142],"category_scores_gemma":[0.006228133,0.0004874528,0.00035657,0.0004512929,0.001006219,0.0002732244,0.0004897537,0.001094612,0.00006583129],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005647127,"about_ca_system_score_gemma":0.00096005,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004564432,"about_ca_topic_score_gemma":0.0003841421,"domain_scores_codex":[0.992979,0.001125697,0.002102816,0.001333814,0.001184975,0.001273721],"domain_scores_gemma":[0.987651,0.007448076,0.002291648,0.001813357,0.0003891416,0.000406801],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3039244,0.2751453,0.246195,0.0003177148,0.002523321,0.005195677,0.01827299,0.000005634248,0.003792205,0.0001174807,0.1285859,0.01592445],"study_design_scores_gemma":[0.5609838,0.03447393,0.3450088,0.0001735582,0.0004407406,0.00008236734,0.003688765,0.00003994147,0.000854252,0.00006117423,0.05409345,0.00009917682],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860274,0.0007392065,0.00001999377,0.0002525952,0.001088651,0.003613667,0.0003956427,0.0001349645,0.007727851],"genre_scores_gemma":[0.9963095,0.0001955031,0.0002490193,0.001199007,0.0003738052,0.0002492566,0.0007248599,0.0000797609,0.0006193575],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2570595,"threshold_uncertainty_score":0.9997577,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02672170501286256,"score_gpt":0.3030244134812918,"score_spread":0.2763027084684293,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}